Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03410030 · ClinicalTrials.gov registry record · Phase 1
Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)
A Phase 1 study, sponsored by HonorHealth Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT03410030 is a Phase 1 study that has completed, run by HonorHealth Research Institute. The registered enrollment target is 27 participants.
The verdict
NCT03410030, a Phase 1 study, has completed, sponsored by HonorHealth Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to see if a treatment regimen with a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancreatic cancer.
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Ascorbic Acid
- DRUG Paclitaxel protein-bound
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2017-12-15 |
| Est. Completion | 2022-01-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03410030
The ClinicalTrials.gov registry entry for NCT03410030 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HonorHealth Research Institute, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT03410030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03410030 about?
NCT03410030 is a clinical study titled "Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)". The purpose of this study is to see if a treatment regimen with a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancreatic cancer.
What is the current status of trial NCT03410030?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2017-12-15. Estimated completion is 2022-01-10.
What interventions are being tested in trial NCT03410030?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), Ascorbic Acid (DRUG), Paclitaxel protein-bound (DRUG).
Who is sponsoring clinical trial NCT03410030?
This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.